225 related articles for article (PubMed ID: 17404088)
1. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Shinozaki M; O'Day SJ; Kitago M; Amersi F; Kuo C; Kim J; Wang HJ; Hoon DS
Clin Cancer Res; 2007 Apr; 13(7):2068-74. PubMed ID: 17404088
[TBL] [Abstract][Full Text] [Related]
2. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Mori T; O'Day SJ; Umetani N; Martinez SR; Kitago M; Koyanagi K; Kuo C; Takeshima TL; Milford R; Wang HJ; Vu VD; Nguyen SL; Hoon DS
J Clin Oncol; 2005 Dec; 23(36):9351-8. PubMed ID: 16361635
[TBL] [Abstract][Full Text] [Related]
3. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
5. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
6. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract][Full Text] [Related]
7. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
9. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
[TBL] [Abstract][Full Text] [Related]
10. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Koyanagi K; Mori T; O'Day SJ; Martinez SR; Wang HJ; Hoon DS
Cancer Res; 2006 Jun; 66(12):6111-7. PubMed ID: 16778184
[TBL] [Abstract][Full Text] [Related]
11. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
Daniotti M; Vallacchi V; Rivoltini L; Patuzzo R; Santinami M; Arienti F; Cutolo G; Pierotti MA; Parmiani G; Rodolfo M
Int J Cancer; 2007 Jun; 120(11):2439-44. PubMed ID: 17315191
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
[TBL] [Abstract][Full Text] [Related]
13. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
14. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis.
Mellado B; Colomer D; Castel T; Muñoz M; Carballo E; Galán M; Mascaró JM; Vives-Corrons JL; Grau JJ; Estapé J
J Clin Oncol; 1996 Jul; 14(7):2091-7. PubMed ID: 8683241
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
17. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Kuo C; Wang HJ; Milford R; Morton DL; Hoon DS
Clin Cancer Res; 2006 Feb; 12(4):1137-43. PubMed ID: 16489066
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
Huang SK; Hoon DS
Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
